Klaus Früh

Title: Klaus Früh: Innovator in Recombinant CMV Vectors

Introduction

Klaus Früh is a notable inventor based in Portland, OR (US). He has made significant contributions to the field of biotechnology, particularly in the development of recombinant vectors. With a total of 2 patents, his work focuses on advancing immunological responses through innovative methodologies.

Latest Patents

Früh's latest patents include groundbreaking research on CMV glycoproteins and recombinant vectors. These patents disclose recombinant CMV vectors that may comprise a heterologous antigen capable of repeatedly infecting an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may also include a deleterious mutation in the US11 glycoprotein or a homolog thereof, showcasing his commitment to enhancing vaccine efficacy.

Career Highlights

Klaus Früh is affiliated with Oregon Health & Science University, where he continues to push the boundaries of scientific research. His work has garnered attention for its potential applications in immunotherapy and vaccine development.

Collaborations

Früh collaborates with esteemed colleagues such as Louis Picker and Scott G Hansen, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Klaus Früh's contributions to the field of biotechnology through his patents and collaborations highlight his role as a leading inventor in the development of recombinant CMV vectors. His work promises to have a lasting impact on immunological research and vaccine development.